Member Directory - Pharmaceutical Advisory Board
Primary tabs
Chair: Charles Flexner
Objectives:
- Engage industry in conversations and serve as a key resource to identify barriers in development and to encourage production of LA/ER ARV’s
- Identify additional experts who can make meaningful contributions to LA/ER topic-specific focus groups, including the generation of educational materials and consensus publications.
Charles W. Flexner, MD, is the Principal Investigator of the Long Acting/Extended Release Antiretroviral Resource Program (LEAP). Conflict of Interest: Dr. Flexner has reported having potential financial conflicts of interest within the past 12 months, or anticipated within the coming 12 months, with the following entities: Algernon Pharmaceuticals; Gilead; Merck; Mylan Pharmaceuticals; ViiV Healthcare. |
Daniel E Cohen, MD, is a Group Medical Director in Clinical Development at AbbVie. Conflict of Interest: Dr. Cohen is an employee and stockholder of AbbVie. |
Daria Hazuda, PhD, trained as a biochemist at the State University of New York at Stony Brook, N.Y. Conflict of Interest: None disclosed. |
Magali Hickey is the Director of Formulation Development at Alkermes Inc. Conflict of Interest: None disclosed. |
Dr. James F. Rooney joined Gilead Sciences in 1996 as Vice President of Clinical Research and in 2004 became Vice President of Medical Affairs. Conflict of Interest: None disclosed. |
Bill Spreen, Pharm.D, is a Director of Research and Development at ViiV Healthcare and based in Research Triangle Park, North Carolina. Conflict of Interest: None disclosed. |